Source: Clinical & Translational Science

Marinella Lauriola Arianna Pani Giovanbattista IppolitiAndrea MortaraStefano MilighettiMarjieh MazenGianluca PerseghinDaniele PastoriPaolo GrossoFrancesco Scaglione

doi:10.1111/cts.12860

Full study here.

Abstract

Conflicting evidence regarding the use of hydroxychloroquine and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection do exist.

We performed a retrospective single‐center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease (COVID‐19). Of these 297 were in combination treatment, 17 were on hydroxychloroquine alone and 63 did not receive any of these two drugs because of contraindications. The primary endpoint was in‐hospital death.

Mean age was 71.8±13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in hydroxychloroquine and 102 in hydroxychloroquine + azithromycin group (log‐rank test for Kaplan‐Meier curve p<0.001).

At multivariable Cox proportional hazard regression analysis, age (hazard ratio [HR] 1.057, 95% confidence interval [CI] 1.035‐1.079, p<0.001), mechanical ventilation/CPAP (HR 2.726, 95%CI 1.823‐4.074, p<0.001), C Reactive Protein above the median (HR 2.191, 95%CI 1.479‐3.246, p<0.001) were directly associated with death, whilst use of hydroxychloroquine + azithromycin (vs. no treatment) (HR 0.265, 95%CI 0.171‐0.412, p<0.001) was inversely associated.

In this study, we found reduced in‐hospital mortality in patients treated with a combination of hydroxychloroquine and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.








Related:
The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study

C19study.com update: Now 88 international studies (51 peer reviewed) show positive hydroxychloroquine treatment outcomes

Quinine worked against the Spanish Flu in 1918

Hydroxychloroquine is Effective and Safe for the Treatment of COVID-19, and May be Universally Effective When Used Early Before Hospitalization: A Systematic Review

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »